Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Monday 15 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

Sales & Marketing

omnichannel marketing concept, puzzle pieces

Omnichannel didn’t fail biopharma. Our metrics did.

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional.

Market Access

Images of pills on dominoes pieces, one being removed from the line

UK pharma policy at a turning point: NICE threshold reform, ...

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

R&D

Businessman looking at cityscape

Future glances: More change, more tech, more harmonisation

According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe

Market Access

US and UK flags in the wind

The UK-US drug pricing deal: A welcome step, but not the fin...

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

R&D

cooperation partnership illustration

Closed and Collaborative: Mergers, acquisitions, and partner...

Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry

Sales & Marketing

12 Questions with Rebecca Douglas

Sponsored

12 Questions with Rebecca Douglas

Rebecca Douglas is a strategic leader with a passion for nurturing talent.

Digital

illustration of AI style auto generation flow diagram

Could GenAI auto-generate entire regulatory dossiers?

Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from acro

Load more results

Sales & Marketing

Sales & Marketing

omnichannel marketing concept, puzzle pieces

Omnichannel didn’t fail biopharma. Our metrics did.

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional.

Sales & Marketing

HCP and patient looking positive

Sponsored

Bridging science and strategy: Medical Affairs at the heart ...

In this sponsored podcast, Cheryl Lubbert and Carolyn Whiting of Reverba discuss a new approach to pharma marketing, omnichannel, and medical affairs.

Digital

Digital

AI screening of lungs in human body digital display

Garbage in, garbage out: The hidden data crisis in pharma

This hidden data crisis is the fundamental barrier to scaling AI in the life sciences sector.

Digital

e-clinical trials concept

How integrated patient experience platforms are revolutionis...

AI-powered integrated platforms offer an elemental shift in the way that clinical trials are conducted.

Market Access

Market Access

Images of pills on dominoes pieces, one being removed from the line

UK pharma policy at a turning point: NICE threshold reform, ...

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

Market Access

US and UK flags in the wind

The UK-US drug pricing deal: A welcome step, but not the fin...

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

Editor's Picks

AC Immune says Parkinson's drug slows progression

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

Agreement reached on EU's new pharma legislation

UK teams up with Singapore on healthtech regulation

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Oncology

Medically accurate representation of a cancer cell

Radiopharmaceutical innovation: Giving cancer drugs second c...

Molecular recycling could transform the economics and innovation of oncology drug discovery.

Oncology

Tumour representation at cellular level

ESMO 2025 in review: A new era in oncology, from AI to next-...

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

Patients

Patients

pharmaphorum podcast Episode 228, Ruth Chambers, Raparu Consult CIC

The NHS, system burden, and a transformation prescription, w...

Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.

Patients

circle of community in wooden figures

How connection can create impact in healthcare: Patient advo...

At ESMO 2025 in Berlin, VML Health presented the inaugural Patient Advocacy Summit.

Patients

A female patient takes a pharmacy delivery directly

DTC pharma is America’s newest care pathway. TrumpRx has exp...

Today’s DTP platforms vary widely in standards, screening protocols, clinical follow-up, data use, and integration with a patient’s broader care team

R&D

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

R&D

Businessman looking at cityscape

Future glances: More change, more tech, more harmonisation

According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe

R&D

Cells under microscope

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

Editor's Picks

AC Immune says Parkinson's drug slows progression

UK confirms lower clawback rate for NHS medicines

Antibiotic is first approval in FDA national priority scheme

Agreement reached on EU's new pharma legislation

UK teams up with Singapore on healthtech regulation

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company